Coinfection is less commonly observed in individuals around the world, yet it is more
common than the single infection. Around 800 million people worldwide are infected with …

Leishmaniasis is an enigmatic disease that has very restricted options for chemotherapy and
none for prophylaxis. As a result, deriving therapeutic principles for curing the disease has …

Background: Leishmaniases are neglected diseases caused by infection with Leishmania
parasites and there are no human vaccines in use routinely. The purpose of this study was …

Control of the intracellular parasite Leishmania (L.) requires the activation of strong type 1
cellular immune responses. Towards this goal, in the present study, a multiepitope chimeric …

Immunotherapy, a treatment based on host immune system activation, has been shown to
provide a substitute for marginally effective conventional chemotherapy in controlling …

The control of human visceral leishmaniasis (VL) is hard since there are no vaccines
available as well as the treatment is hampered by toxicity and resistant parasites …

Haemaphysalis longicornis is an obligate hematophagous ectoparasite that transmits a
variety of pathogens causing life‑threatening diseases in humans and animals …

Visceral leishmaniasis (VL) is the third most severe infectious parasitic disease and is
caused by the protozoan parasite Leishmania. To control the spread of the disease in …

Background Available therapeutics for visceral leishmaniasis (VL), a deadly parasitic
infection, are usually associated with inadequate efficacy and adverse aftereffects. Further …

There are no approved vaccines yet for human visceral leishmaniasis (VL), the most severe
form of the leishmaniasis clinical manifestations that is fatal in over 95% of untreated cases …